Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. (10th March 2022)

• Record Type: Journal Article
• Authors: FitzGerald, Richard; Dickinson, Laura; Else, Laura; Fletcher, Thomas; Hale, Colin; Amara, Alieu; Walker, Lauren; Penchala, Sujan Dilly; Lyon, Rebecca; Shaw, Victoria; Greenhalf, William; Bullock, Katie; Lavelle-Langham, Lara; Reynolds, Helen; Painter, Wendy; Holman, Wayne; Ewings, Sean; Griffiths, Gareth; Khoo, Saye
• Is Part Of: Clinical infectious diseases. Volume 75:Number 1(2022)
• Page Start: e525
• Page End: e528
• Publication Date: 2022-03-10
• Subjects: molnupiravir -- pharmacokinetics -- nonplasma -- SARS-CoV-2 -- COVID-19; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciac199
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at SARS-CoV-2 transmission sites in 12 patients enrolled in AGILE Candidate-Specific Trial-2. Saliva, nasal, and tear NHC concentrations were 3%, 21%, and 22% that of plasma. Saliva and nasal NHC were significantly correlated with plasma ( P < .0001). Clinical Trials Registration . NCT04746183.